Kap Elisabeth J, Popanda Odilia, Chang-Claude Jenny
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120 Heidelberg, Germany.
Division of Epigenomics & Cancer Risk Factors, DKFZ, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Pharmacogenomics. 2016 May;17(7):755-94. doi: 10.2217/pgs-2015-0017. Epub 2016 May 16.
Several new chemotherapeutic agents have become available for the treatment of colorectal cancer, which has led to increased complexity in treatment planning. Treatment decision making for individual patients could be facilitated if guided by predictive and prognostic markers. As most cytotoxic drugs induce DNA damage, the DNA damage repair pathways hold potential for yielding such biomarkers. Here, we review the current evidence of a possible involvement of the nucleotide excision repair pathway in the efficacy of chemotherapeutic agents used in the treatment of colorectal cancer. Although a large number of studies have been conducted, they are generally of moderate size and heterogeneous in design. Up to date no firm conclusions can be drawn to translate these results into the clinic. We recommend further comprehensive investigations of the nucleotide excision repair pathway in large patient studies that include both discovery and validation cohorts.
几种新的化疗药物已可用于治疗结直肠癌，这导致治疗方案的复杂性增加。如果有预测性和预后性标志物的指导，可为个体患者的治疗决策提供便利。由于大多数细胞毒性药物会诱导DNA损伤，DNA损伤修复途径具有产生此类生物标志物的潜力。在此，我们综述了核苷酸切除修复途径可能参与结直肠癌治疗中所用化疗药物疗效的当前证据。尽管已经进行了大量研究，但这些研究通常规模适中且设计各异。迄今为止，尚无法得出确凿结论将这些结果应用于临床。我们建议在包括发现队列和验证队列的大型患者研究中对核苷酸切除修复途径进行进一步的全面研究。
